1
|
Molecular Profiling of EGFR Status to Identify Skin Toxicity in Colorectal Cancer: A Clinicopathological Review. CURRENT HEALTH SCIENCES JOURNAL 2019; 45:127-133. [PMID: 31624638 PMCID: PMC6778291 DOI: 10.12865/chsj.45.02.01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Figures] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Accepted: 06/20/2019] [Indexed: 11/24/2022]
Abstract
Colorectal cancer (CRC) represents an important health problem, being the third most common type of cancer. In Romania, the CRC incidence has doubled over the years. Both environmental factors and genetic susceptibility are very important for the pathogenesis of CRC. The epidermal growth factor receptor (EGFR) plays an extremely important role in CRC tumorigenesis. Overexpression or dysregulation of EGFR pathway molecules are frequently associated with tumor aggressiveness and patient response to treatment. Based on these considerations, EGFR became one of the first targets of molecular therapies used in CRC. At present, cetuximab and panitumumab are considered to be essential in the treatment of patients with metastatic colorectal cancer expressing the KRAS wild-type gene and EGFR. The main adverse effect for both cetuximab and panitumumab is skin toxicity, present in approximately 80% of patients. The risk of secondary infections, in particular of bacterial infections, is also increased. Cases of staphylococcal infection associated with skin peeling, cellulite, erysipelas, and even Staphylococcus sepsis, were reported. For a long time cutaneous toxicity has been a positive predictor in the efficacy of anti-EGFR treatment, but compliance with treatment and the quality of life of patients with metastatic CRC decreases in the presence of these skin reactions. That is why we emphasize the necessity and importance of using a modern method (molecular analysis of gene polymorphisms possibly supplemented by targeted confocal laser endomicroscopy) to identify a molecular diagnosis, in order to foresee and prevent the appearance of skin reactions and to manage skin toxicity.
Collapse
|
2
|
Spessotto P, Fornasarig M, Pivetta E, Maiero S, Magris R, Mongiat M, Canzonieri V, De Paoli P, De Paoli A, Buonadonna A, Serraino D, Panato C, Belluco C, Cannizzaro R. Probe-based confocal laser endomicroscopy for in vivo evaluation of the tumor vasculature in gastric and rectal carcinomas. Sci Rep 2017; 7:9819. [PMID: 28852161 PMCID: PMC5575283 DOI: 10.1038/s41598-017-10963-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2017] [Accepted: 08/17/2017] [Indexed: 12/17/2022] Open
Abstract
Probe-based Confocal Laser Endomicroscopy (pCLE) is a powerful imaging technique that allows to perform gastrointestinal endomicroscopy at subcellular resolution. The aim of this study was to assess the use of pCLE to evaluate tumor angiogenesis in rectal and gastric cancers. A total of 35 consecutive patients with gastric and 91 with rectal carcinomas underwent endoscopy and pCLE during the same examination. Vascular assessment was based on vessel shape and size, vessel permeability and blood flow, and allowed the creation of an angiogenic score ranging from 0, for normal vasculature, to 4, for aberrant vasculature. A significant difference for the presence of vessels with large diameter and defective blood flow was found between rectal and gastric cancers. Overall, rectal cancers displayed a higher angiogenic score compared to gastric cancers. Conventional therapy induced a striking reduction in the angiogenic score only in rectal cancer patients. Taken together, our findings suggest that the pCLE technology is suitable for the evaluation of the tumor microvasculature abnormalities. Therefore, the real-time assessment of the vasculature status may represent a promising approach to predict the efficacy of the treatments and improve the clinical management of patients with gastric or rectal carcinomas.
Collapse
Affiliation(s)
- Paola Spessotto
- Molecular Oncology, Department of Translational Research, CRO-IRCCS, National Cancer Institute, Aviano, Italy
| | - Mara Fornasarig
- Gastroenterology, CRO-IRCCS, National Cancer Institute, Aviano, Italy
| | - Eliana Pivetta
- Molecular Oncology, Department of Translational Research, CRO-IRCCS, National Cancer Institute, Aviano, Italy
| | - Stefania Maiero
- Gastroenterology, CRO-IRCCS, National Cancer Institute, Aviano, Italy
| | - Raffaella Magris
- Gastroenterology, CRO-IRCCS, National Cancer Institute, Aviano, Italy
| | - Maurizio Mongiat
- Molecular Oncology, Department of Translational Research, CRO-IRCCS, National Cancer Institute, Aviano, Italy
| | | | - Paolo De Paoli
- Scientific Directorate, CRO-IRCCS, National Cancer Institute, Aviano, Italy
| | - Antonino De Paoli
- Radiation Oncology, CRO-IRCCS, National Cancer Institute, Aviano, Italy
| | - Angela Buonadonna
- Medical Oncology, CRO-IRCCS, National Cancer Institute, Aviano, Italy
| | - Diego Serraino
- Epidemiology and Biostatistics, CRO-IRCCS, National Cancer Institute, Aviano, Italy
| | - Chiara Panato
- Epidemiology and Biostatistics, CRO-IRCCS, National Cancer Institute, Aviano, Italy
| | - Claudio Belluco
- Surgical Oncology, CRO-IRCCS, National Cancer Institute, Aviano, Italy
| | - Renato Cannizzaro
- Gastroenterology, CRO-IRCCS, National Cancer Institute, Aviano, Italy.
| |
Collapse
|